ClinicalTrials.gg
CompletedNCT06132204Updated Oct 15, 2024

Pharmacokinetic and Safety Studies of HRS-7535 in Subjects With Moderate Renal Insufficiency and Healthy Subjects

A Phase 1 interventional study of HRS-7535 Tablets in Type 2 Diabetes, sponsored by Shandong Suncadia Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-15.

Sponsored by Shandong Suncadia Medicine Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 81 studies in Diabetes Mellitus, Type 2 by Jiangsu HengRui Medicine Co., Ltd. — 8 open to participants now, 11 under way, 4 of them phase 3. Diabetes Mellitus, Type 2 · Jiangsu HengRui Medicine Co., Ltd..

Enrollment
71st of 81
16 · median 80
Started
2023
with 9 others
Phase 1
48 of 81
4 open now
Registered
52nd of 81
by date

Among the 81 studies in Diabetes Mellitus, Type 2 by Jiangsu HengRui Medicine Co., Ltd., this one is the 71st largest by enrollment, is one of 10 that started in 2023, is one of 48 in phase 1, and was the 52nd registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

8 of the 81 studies in Diabetes Mellitus, Type 2 by Jiangsu HengRui Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Diabetes Mellitus, Type 2 by Jiangsu HengRui Medicine Co., Ltd., or all of them as a file.
02

Study summary

The study is being conducted to evaluate and compare the pharmacokinetics of HRS-7535 tablets in subjects with moderate renal insufficiency and healthy subjects.

03

Conditions studied

  • Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age range from 18 to 65 years old (including both ends, subject to signing the form), both male and female;
  2. The subject's body weight is ≥ 50 kg, and the (BMI) is within the range of 19.0\~32.0 kg/m2 (including both ends);
  3. From the signing of the informed consent form until 6 months after the last administration, the subject (including partner) has no family planning and is willing to use the high-efficiency measures specified in the plan;
  4. Before the experiment, voluntarily sign an informed consent form and have a thorough understanding of the experiment content, process, and potential adverse reactions.
  5. For Moderately renal insufficiency subjects, 30 mL/min ≤ \<60, and the renal function status is stable. Did not use drugs for treating renal insufficiency or was determined by the researcher to be stable in taking drugs for treating renal insufficiency for more than 4 weeks.
  6. For Healthy subjects,90 mL/min \< GFR;there was no history of chronic kidney disease during screening. Weight, age, and gender should meet the matching requirements for subjects with moderate renal insufficiency.

Exclusion criteria

Exclusion Criteria:

  1. During screening period, glutamate (AST) ≥ 2 × (ULN); Glutamate aspartate aminotransferase (ALT) ≥ 2 × ULN; Total (TBIL) ≥ 1.5 × ULN;
  2. Abnormal and 12 lead (ECG), or ECG >450 ms (corrected according to Fridericia's formula);
  3. surface antigen is positive, antibody is positive, Treponema pallidum antibody is positive, antibody is positive;
  4. Have a history of life-threatening diseases within 5 years (excluding basal cell skin cancer or squamous cell skin cancer);
  5. Previous history of medullary thyroid cancer, multiple endocrine neoplasia type 2 or family history, previous history of pancreatitis or symptomatic gallbladder disease;
  6. Previous clinical history of gastric emptying abnormalities (such as gastric outlet obstruction), severe chronic gastrointestinal diseases (such as inflammatory bowel disease and active ulcers);
  7. Other clinically significant diseases (including but not limited to gastrointestinal, renal, hepatic, neurological, hematological, endocrine, tumor, lung, immune, psychiatric, or cardiovascular diseases) found within the first 6 months of screening;
  8. Have undergone gastrointestinal surgery that can cause malabsorption before screening, or have taken drugs that have a direct impact on gastrointestinal peristalsis for a long time;
  9. Have used drugs that may affect glucose metabolism within the first month of screening (such as systemic and non-selective drugs) β Receptor blockers, monoamine oxidase inhibitors);
  10. Have used glucagon like peptide peptide-1 receptor agonists within the first 3 months of screening;
  11. Individuals with severe allergic diseases or known or suspected allergies or allergies to any component of the study drug (including multiple drug and food allergies);
  12. Discontinuation of glucagon like peptide-1 receptor agonist therapy due to safety/tolerance reasons or lack of efficacy in the past;
  13. Have received clinical trial treatment of any drug or medical device within the first 3 months or 5 half-lives (whichever is longer) before screening, or plan to participate in clinical trials of other drugs or medical devices during the trial period;
  14. Screening for individuals who have consumed more than 14 units of alcohol per week within the first 6 months or who have taken alcoholic products 48 hours before administration; Or positive for alcohol breath test;
  15. Smoking more than 5 cigarettes per day within the first 3 months of screening or using any tobacco products 48 hours before administration;
  16. Exercise vigorously within 48 hours before administration;
  17. Those who have a history of drug abuse within the past five years or have used drugs in the three months prior to the trial; Or positive for urine drug screening;
  18. Donate ≥ 200 mL of blood within one month before screening; Or select trauma or surgical major surgeries who have donated blood ≥ 400 mL or lost blood ≥ 400 mL within the first 3 months;
  19. Inability to tolerate venous puncture blood collection or needle dizziness;
  20. Have special dietary requirements and cannot follow a unified diet;
  21. Patients with fasting blood glucose>11.1 mmol/L;
  22. Subjects who the researchers believe have other factors that are not suitable for participating in this experiment.
  23. For Moderately renal insufficiency subjects: Have a history of kidney transplantation;Urinary incontinence or oliguria (such as\<400 mL/d);Within 14 days prior to administration, medication other than those used to treat renal insufficiency and other accompanying diseases has been taken that affects the experiment; After examination and inquiry, according to the judgment of the researcher, there are serious accompanying diseases that pose a serious threat to the patient's safety or affect the patient's ability to complete this study.
  24. For Healthy subjects: Have taken any medication that affects the experiment within 14 days before administration; Those who have clinical significance in judging abnormalities through comprehensive physical examination, vital signs, laboratory examination, X-ray chest X-ray, abdominal ultrasound examination, etc.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    HRS-7535 Tablets-Moderately renal insufficiency subjects

    Drug: HRS-7535 Tablets

  • Experimental
    HRS-7535 Tablets-Healthy subjects

    Drug: HRS-7535 Tablets

Interventions

06

What researchers measure

Primary outcomes

  1. PK parameters of HRS-7535: Cmax

    Time frame: 0 hour to 48 hour after administration

  2. PK parameters of HRS-7535: AUC0-t

    Time frame: 0 hour to 48 hour after administration

  3. PK parameters of HRS-7535: AUC0-inf

    Time frame: 0 hour to Infinity hour after administration

Secondary outcomes

  1. PK parameters of HRS-7535: Tmax

    Time frame: 0 hour to 48 hour after administration

  2. PK parameters of HRS-7535: t1/2

    Time frame: 0 hour to 48 hour after administration

  3. PK parameters of HRS-7535: CL/F

    Time frame: 0 hour to 48 hour after administration

  4. PK parameters of HRS-7535: Vz/F

    Time frame: 0 hour to 48 hour after administration

  5. Adverse events

    Time frame: from ICF signing date to day 7 (+3)after administration

07

Study locations

1 site
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan 450052, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2023 to primary completion in Mar 2024, 2 months.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 2 months is below that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2023
First posted
Nov 15, 2023
StartActual
Dec 21, 2023
Primary completionActual
Mar 13, 2024
CompletionActual
Mar 13, 2024
Last update
Oct 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06132204
Responsible party
Sponsor
First posted
Nov 15, 2023
Start date
Dec 21, 2023
Primary completion
Mar 13, 2024
Completion
Mar 13, 2024
Last update
Oct 15, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HRS-7535

Start the discussion